Results 31 to 40 of about 6,882 (175)

Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem celltransplantation

, 2022
Background/aim: Thrombocytopenia is a common complication following hematopoietic stem cell transplantation (HSCT). Eltrombopag has been used in thrombocytopenia treatment after liscr in recent years.
DEMİROĞLU, HALUK, KARADENİZ, MİNE, GÖKER, HAKAN, MALKAN, ÜMİT YAVUZ, ÇINAR, OLGU ERKİN, AKSU, SALİH, Velet, Mustafa, BÜYÜKAŞIK, YAHYA, ÖZCEBE, OSMAN İLHAMİ, SAYINALP, NİLGÜN, HAZNEDAROĞLU, İBRAHİM CELALETTİN, Erdogdu, Batuhan, KARATAŞ, AYŞE   +12 more
core   +1 more source

Eltrombopag Inhibits Metastasis in Breast Carcinoma by Targeting HuR Protein

, 2023
Eltrombopag is a small molecule TPO-R agonist that has been shown in our previous studies to inhibit tumor growth by targeting Human antigen R (HuR) protein.
Yuying Zhu, Rui Zhang, Liuqing Yang, Yao Chen, Pei Zhang, Feiyun Wang, Jiange Zhang, Guoqiang Lin, Zhu, Yuying, Zhang, Pei, Chen, Yao, Wang, Feiyun, Lin, Guoqiang, Yang, Liuqing, Zhang, Rui, Zhang, Jiange   +15 more
core   +1 more source

Eltrombopag in Good’s Syndrome [PDF]

, 2014
Good’s syndrome is a rare acquired immunodeficiency associated with thymoma. Eltrombopag is a thrombopoietin receptor agonist and has been shown to be a valuable supplement to the treatment of several types of refractory cytopenias.
Håvard Anton Kristiansen, Signe Spetalen, Dag Heldal, Yngvar Fløisand   +3 more
core   +1 more source

Eltrombopag improves refractory thrombocytopenia in patients with Sjögren's syndrome

Science Progress, 2022
Introduction: Eltrombopag, a kind of thrombopoietin (TPO) receptor agonist, plays the role on the megakaryocyte to activate the platelet production and rapidly increase the number of circulating platelets in patients with primary immune thrombocytopenia (
Liping Xu, Yan Zhang, Na Lin, Xinwei Song, Qiaoding Dai   +4 more
doaj   +1 more source

A Real-World Observation of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) in Lymphoma Patients With Chemotherapy Induced Thrombocytopenia

Frontiers in Oncology, 2021
This real-world, observational study aimed to assess and compare the clinical efficacy and safety of eltrombopag with recombinant human thrombopoietin (rhTPO) in the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with lymphoma.
Qiuhua Zhu, Shimei Yang, Wenbin Zeng, Mingjie Li, Zebing Guan, Lanlan Zhou, Hong Wang, Yanan Liu, Yanmin Gao, Shiqiu Qiu, Chaolun Chen, Huan Li, Shanshan Zheng, Yuemei Yuan, Hanling Zhang, Xueyi Pan   +15 more
doaj   +1 more source

Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis

Clinical and Applied Thrombosis/Hemostasis, 2021
Eltrombopag is an orally administered, non-peptide, thrombopoietin receptor agonist which initiates thrombopoietin signaling and stimulates the production of normally functioning platelet. We aimed to do a systematic review and meta-analysis of currently
Hafiz Abdul Waqas Ahmed MD, Ahmed Taher Masoud MD, Jia Han MD, PhD, Ahmed Adel Sofy MD, Ahmed Saeed Ahmed MD, Ahmed Taha Abdesattart MD, Emmanuel Kwateng Drokow MD, PhD, Kai Sun MD, PhD   +7 more
doaj   +1 more source

Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study

Chinese Medical Journal, 2022
Background:. Recombinant human thrombopoietin (rh-TPO) and eltrombopag are two distinct TPO receptor agonists (TPO-RAs) with different mechanisms. During the pandemic, when immunosuppressive medications are controversial, switching to another TPO-RA may ...
Xuan Cai, Haixia Fu, Xiangyu Zhao, Jin Lu, Qian Jiang, Yingjun Chang, Xiaojun Huang, Xiaohui Zhang, Yuanyuan Ji   +8 more
doaj   +1 more source

Eltrombopag in treatment of refractory primary immune thrombocytopenia: case report

Клиническая онкогематология, 2013
We present clinical case that demonstrates high efficiency of eltrombopag for the treatment of immune thrombocytopenia. It is shown that stable effect may persist after a course of eltrombopag therapy during 2 months. Eltrombopag is highly effective with
G. A. Dudina, I. N. Kontievskiy, V. N. Perova   +2 more
doaj   +1 more source

Use of Thrombopoietin Receptor Agonists in Pregnancy: A Review of the Literature

Hematology/Oncology and Stem Cell Therapy, 2022
The management of immune thrombocytopenic purpura (ITP) involves several lines of therapy such as corticosteroids and intravenous immunoglobulin. With the emergence of novel therapies such as thrombopoietin receptor agonists (TPO-RAs), there has been a ...
Jude Howaidi, Abdullah M. AlRajhi, Ali Howaidi, Fouad H. AlNajjar, Imran K. Tailor   +4 more
doaj   +1 more source

ELTROMBOPAG THERAPHY IN CASES OF APLASTIC ANEMIA: A CASE REPORT

, 2023
: Eltrombopag Theraphy In Cases Of Aplastic Anemia: A Case Report. Management of cases of aplastic anemia is challenge. The definitive treatment is bone marrow transplantation, but it is expensive, the complication rate is high and the success rate is ...
Suastika, Ngakan Ketut Wira, Wisadianta, Gede Resha   +1 more
core   +1 more source